Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
Tesla earnings: Shares fall as market focuses on uncertainty in near term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,317.20 | 26.50 | -0.28% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,238.57 | 503.96 | 1.08% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,160.15 | 192.17 | 0.74% |
| NASDAQ | 23,231.47 | 289.67 | 1.26% |
| Nikkei 225 | 49,299.65 | 658.04 | 1.35% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,797.83 | 59.39 | 0.88% |
| S&P/ASX 200 | 9,019.00 | 25.20 | -0.28% |
| SSE Composite Index | 3,950.31 | 27.90 | 0.71% |